investor updat nan focus vector studi
attend north american neuromodul societi confer nan
relev compani focus spinal cord stimul deep brain stimul
db pain manag primarili relat buy-rat
sell-rat coverag held investor updat
confer new inform present compani vector
studi view lead sourc evid space could
give abil develop market approach custom
wait develop new evid interim result show trial
success rate high dose trial success three month
subject least pain reduct see one factor help
busi continu grow market rate peg low-
posit updat broader rtg busi
grand scheme view small posit rate buy given
view continu grow msd rate despit tougher comp near
term given strength restor therapi group rtg minim invas
therapi group mitg diabet overcom near-term headwind cardiac
vascular group cvg given headwind dcb busi due paclitaxel
concern lvad busi increas competit chang heart
transplant guidelin updat nan includ broader rtg updat gave
us increment confid growth spine pain near term db
continu pressur pipelin help
addit takeaway investor updat back
discuss key takeaway session host geoff martha evp
group presid rtg marshal stanton svp presid pain therapi
mike dali vice-president gm brain modul busi back note
valuat pt base ep estim
trade ep april end compar peer like
trade data key metric
compani account thomson reuter ub estim ub adjust ep state goodwill-rel charg adjust abnorm econom item analyst
judgement valuat base averag share price year base share price jan estimate
report prepar ub secur llc analyst certif requir disclosur begin
page ub seek busi compani cover research report result investor
awar firm may conflict interest could affect object report investor consid
report singl factor make invest decis
ub research thesi map guid think report
 obtain long-term growth target revenu growth
ye recent trend shown portfolio reach m-hsd level growth
divis grow togeth model xfx growth
 gain share grow spine
ye analysi ub evid lab spine neuro survey data show like
gain share spine conserv model core spine growth next year market
rate would higher includ enabl technolog report divis
 growth rebound diabet continu
ye growth shift dramat neg strong double-digit past
quarter analysi ub evid lab diabet survey suggest like gain
share diabet given technolog view favor model xfx growth
diabet busi tough comp
buy rate base view consist achiev msd revenu growth given
product line-up pipelin on-going differenti invest high growth area consensu
appear sceptic abil keep growth given challeng comp keep share
discount despit recent organ growth rang
analysi data ub evid lab diabet physician patient survey show
mostli like gain share grow market product view favor analyz
data ub evid lab survey spine neuro surgeon suggest
like gain share spinal implant spinal cord stimul market final analysi
pipelin margin goal recent trend suggest lrp goal achiev
trade ep discount peer like
recent peak consensu model revenu growth ep growth
upsid downsid
ebit margin
compani descript medtron global develop manufactur market medic devic use
broad rang intervent medic specialti compani busi
geoff martha evp group presid rtg
mr martha highlight turnaround rtg busi recent quarter
driven brain pain therapi pain turnaround driven
intelli evolv workflow snapshot stage db pressur
verg meaning product launch includ next
gener primari cell sens devic direct lead
cranial mount db beyond mr martha view improv rtg
notabl bit lost recent nois busi structur
invest pipelin allow grow market
specif across busi sole focus
therapeut area goal
last month spine growth stabil around
expect improv quarter see momentum
thing especi mazor actual report brain unit
help pull enabl technolog like o-arm also
enabl volum pull pull-through take time increasingli
put place earn-out mazor unit given demand robot hospit
budget constraint larger proport mazor placement
earn-out versu third expect time think
mayb robot sold way especi physician move
site surgeri outsid hospit
marshal stanton svp presid pain therapi
see pain stim market low-teen grower grow slightli
ahead rate near term window peg expect
market growth note market dynam tough call
stage highlight intelli smallest product market
advantag recharg technolog compani
space make batteri intelli abl recharg hour
less also maintain charg capac year less batteri fade
competitor view evolv workflow key success
paresthesia map start trial test high dose look
pain reduct day next step move bipol tri
hd final step use tradit tonic low dose yield good result
vector studi think drive broader adopt intelli
look forward object move beyond subject measur
pain creat predict model improv clinic econom outcom
also pain accurian nerv ablat system includ puls rf thermal rf
cool rf give physician option form consist
predict lesion format also design eas use target drug
deliveri new synchrom ii system clinician programm help
busi move back growth work myptm person therapi
manag control workflow treat chronic pain data shown least
patient use pump abl get oral opioid one year
run trial call embrac tdd wean subject system
opioid protocol final fall interim look
year intervent two new product come
next year kyphon assist direct cannula improv
control balloon inflat osteocontrol product acceler
bone access bone biopsi
mike dali vice-president gm brain modul busi
given posit market leader db competit launch
busi two strateg imper protect market
share rebuild foundat regain share drive growth
near term trench fight retain market share launch
visual program june small posit ad next-
gener devic sens near term like lose
share new market end see
potenti healthi growth launch longer term see
potenti close loop therapi drive improv outcom increas devic
longev reduc side effect reduc program burden beyond
time-frame think disrupt market cranial mount devic
could improv cosmesi make faster simpler procedur tunnel
improv comfort charg note also launch db devic
epilepsi nov american epilepsi societi meet db
anterior nucleu thalamu partial onset seizur stage
market develop mode made decis whether move
broadli epilepsi
upsid downsid
ebit margin
upsid upsid case assum organ growth
driven broad-bas product driver includ sever key new product
predic stabl global market price trend upsid case
grow ebit margin higher growth given
modest line leverag fx headwind forecast ep growth
period
base base case assum organ growth
driven broad-bas product driver includ sever key new product
predic stabl global market price trend anticip
grow ebit margin invest numer growth
opportun given modest line leverag forecast ep growth
period
downsid downsid case assum organ growth
new product growth drag competit key area
like tavr diabet stent scenario would includ modest
soften global market price trend condit
anticip grow ebit margin invest
numer growth opportun given modest line leverag
forecast ep growth period
global develop manufactur
market medic devic use broad rang
intervent medic specialti compani
busi segment cvg sale mitg rtg
diabet headquart
encourag sector fundament includ
renaiss big new product driver push innovation-
led growth drumbeat steadi volum increas
popul age emerg market
earli inning util time med-tech risk
rel contain price trend larg stabl
low cost implant find littl traction area
physician prefer med-tech also view favor
polit part solut term abil
improv healthcar outcom lower cost
exposur growth market cardio surgic
breadth diversif invest spinal
robot diabet structur heart add leverag
revenu region
ebit product segment
cardiac vascular
profit tax
profit tax
equival
invest asset
trade payabl st liabil
net incom pref div
net chang work capit
chang debt pref share
flow inc/ dec cash
balanc sheet inc/ dec cash
compani account ub estim ub metric use report figur adjust ub ep ub dilut calcul use ub net incom ad back depreci
buy minor
revenu divis us
ebit ub divis us
compani account ub estim ub metric use report figur adjust ub analyst
valuat method risk statement
price target base ep risk price
target includ slowdown core cardio neuro spine surgic end market
increas competit establish larg cap compani competit
entrant differenti technolog delay key product approv
reject regulatori bodi inabl deliv top-lin growth meet
consensu expect top line miss guidanc consensu
bottom line delay robot launch timelin mitral project meet
expect chang regulatori environ lead longer lead
time higher bar approv
